Silence Therapeutics 향후 성장
Future 기준 점검 2/6
Silence Therapeutics 의 수익은 연간 27.3% 감소할 것으로 예상되는 반면, 연간 수익은 56.2% 로 증가할 것으로 예상됩니다. EPS는 연간 20.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -14.7% 로 예상됩니다.
핵심 정보
-27.3%
이익 성장률
20.24%
EPS 성장률
| Biotechs 이익 성장 | 25.5% |
| 매출 성장률 | 56.2% |
| 향후 자기자본이익률 | -14.73% |
| 애널리스트 커버리지 | Good |
| 마지막 업데이트 | 08 May 2026 |
최근 향후 성장 업데이트
분석 기사 • Aug 12
Silence Therapeutics plc (NASDAQ:SLN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
NasdaqGM:SLN 1 Year Share Price vs Fair Value Explore Silence Therapeutics's Fair Values from the Community and select...분석 기사 • May 11
Silence Therapeutics plc (NASDAQ:SLN) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
The analysts might have been a bit too bullish on Silence Therapeutics plc ( NASDAQ:SLN ), given that the company fell...분석 기사 • Aug 18
Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
As you might know, Silence Therapeutics plc ( NASDAQ:SLN ) last week released its latest second-quarter, and things did...Recent updates
분석 기사 • Feb 05
Revenues Working Against Silence Therapeutics plc's (NASDAQ:SLN) Share Price Following 27% Dive
To the annoyance of some shareholders, Silence Therapeutics plc ( NASDAQ:SLN ) shares are down a considerable 27% in...분석 기사 • Jan 31
Here's Why We're Watching Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Seeking Alpha • Nov 18
Silence Therapeutics: Divesiran Targets High-Burden PV
Summary Silence Therapeutics is advancing its lead RNAi drug, divesiran, for polycythemia vera, with a fully enrolled Phase 2 trial and results expected in Q3 2026. SLN boasts a strong cash position ($100M+), providing runway through 2028 and enabling continued pipeline development without near-term financing risks. The SANRECO trial's design and patient population position divesiran as a potential adjunctive therapy for high-burden PV patients, focusing on reduced phlebotomy frequency and infrequent dosing. While acknowledging clinical and market risks, I maintain a cautiously optimistic outlook, seeing significant upside if Phase 2 data demonstrate efficacy and safety. Read the full article on Seeking Alpha분석 기사 • Oct 19
Here's Why We're Watching Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...분석 기사 • Sep 28
Pinning Down Silence Therapeutics plc's (NASDAQ:SLN) P/S Is Difficult Right Now
With a median price-to-sales (or "P/S") ratio of close to 9.9x in the Biotechs industry in the United States, you could...분석 기사 • Aug 13
Newsflash: Silence Therapeutics plc (NASDAQ:SLN) Analysts Have Been Trimming Their Revenue Forecasts
NasdaqGM:SLN 1 Year Share Price vs Fair Value Explore Silence Therapeutics's Fair Values from the Community and select...분석 기사 • Aug 12
Silence Therapeutics plc (NASDAQ:SLN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
NasdaqGM:SLN 1 Year Share Price vs Fair Value Explore Silence Therapeutics's Fair Values from the Community and select...
내러티브 업데이트 • Aug 08
ALPACAR-360 Success And AstraZeneca Collaboration Will Advance siRNA Pipeline
The upward revision in Silence Therapeutics’ price target reflects significantly improved consensus revenue growth forecasts and a lower future P/E multiple, resulting in an increased fair value estimate from $32.37 to $37.26. What's in the News Silence Therapeutics approved the application of Article 159 of its articles of association, effective from the recent AGM to the next annual general meeting.분석 기사 • May 11
Silence Therapeutics plc (NASDAQ:SLN) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
The analysts might have been a bit too bullish on Silence Therapeutics plc ( NASDAQ:SLN ), given that the company fell...분석 기사 • May 06
Silence Therapeutics plc's (NASDAQ:SLN) Price Is Right But Growth Is Lacking After Shares Rocket 50%
Those holding Silence Therapeutics plc ( NASDAQ:SLN ) shares would be relieved that the share price has rebounded 50...
새로운 내러티브 • Apr 01
ALPACAR-360 Success And AstraZeneca Collaboration Will Advance siRNA Pipeline
The company's strategic partnerships and collaborations could reduce financial risk and enhance revenue growth through shared commercialization and milestone payments.분석 기사 • Mar 22
Silence Therapeutics plc (NASDAQ:SLN) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough
Unfortunately for some shareholders, the Silence Therapeutics plc ( NASDAQ:SLN ) share price has dived 29% in the last...분석 기사 • Mar 06
These Analysts Think Silence Therapeutics plc's (NASDAQ:SLN) Sales Are Under Threat
Market forces rained on the parade of Silence Therapeutics plc ( NASDAQ:SLN ) shareholders today, when the analysts...분석 기사 • Mar 04
We're Keeping An Eye On Silence Therapeutics' (NASDAQ:SLN) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...분석 기사 • Jan 28
Risks Still Elevated At These Prices As Silence Therapeutics plc (NASDAQ:SLN) Shares Dive 26%
Unfortunately for some shareholders, the Silence Therapeutics plc ( NASDAQ:SLN ) share price has dived 26% in the last...분석 기사 • Dec 10
Silence Therapeutics plc (NASDAQ:SLN) May Have Run Too Fast Too Soon With Recent 54% Price Plummet
Silence Therapeutics plc ( NASDAQ:SLN ) shareholders that were waiting for something to happen have been dealt a blow...분석 기사 • Oct 04
Some Shareholders Feeling Restless Over Silence Therapeutics plc's (NASDAQ:SLN) P/S Ratio
You may think that with a price-to-sales (or "P/S") ratio of 38.4x Silence Therapeutics plc ( NASDAQ:SLN ) is a stock...분석 기사 • Aug 18
Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
As you might know, Silence Therapeutics plc ( NASDAQ:SLN ) last week released its latest second-quarter, and things did...분석 기사 • Jun 17
Silence Therapeutics plc's (NASDAQ:SLN) Shareholders Might Be Looking For Exit
You may think that with a price-to-sales (or "P/S") ratio of 26.8x Silence Therapeutics plc ( NASDAQ:SLN ) is a stock...분석 기사 • May 21
Here's Why We're Not Too Worried About Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. By way of example, Silence...분석 기사 • Feb 07
Need To Know: Analysts Are Much More Bullish On Silence Therapeutics plc (NASDAQ:SLN) Revenues
Silence Therapeutics plc ( NASDAQ:SLN ) shareholders will have a reason to smile today, with the analysts making...분석 기사 • Nov 27
Subdued Growth No Barrier To Silence Therapeutics plc (NASDAQ:SLN) With Shares Advancing 65%
Silence Therapeutics plc ( NASDAQ:SLN ) shares have had a really impressive month, gaining 65% after a shaky period...Seeking Alpha • Sep 08
Silence Therapeutics wins FDA’s fast track status for blood cancer therapy
U.K.-based clinical-stage biotech Silence Therapeutics plc (NASDAQ:SLN) announced Thursday that the FDA granted Fast Track Designation to SLN124 as a treatment for polycythemia vera (PV), a type of blood cancer. SLN124, belonging to a drug class called short interfering ribonucleic acid (siRNA) therapeutics, is set to undergo a Phase 1/2 study in PV this year. The FDA offers the Fast Track designation to accelerate the development and review of drugs targeted at serious conditions with unmet medical needs. It allows developers to communicate frequently with the regulator on plans for clinical studies. If certain criteria are met, such programs will also be able to win the Accelerated Approval and Priority Review, enabling them to reach patients sooner. In a clinical trial last year, SLN124 indicated proof of mechanism and was well tolerated among healthy volunteers.Seeking Alpha • Aug 12
Silence Therapeutics prices 5.95M ADSs at $9.50/share
Silence Therapeutics (NASDAQ:SLN) has priced an underwritten offering of 5.95M American Depositary Shares, each representing three ordinary shares, at a price of $9.50/ADS, for aggregate gross proceeds of ~$56.5M. All of the ADSs are being offered by Silence. Offering is expected to close on or about August 16, 2022. Silence intends to use the net proceeds of the offering, together with its existing cash and cash equivalents to fund the advancement of its clinical trials, including its Phase 2 trial of SLN360 in ASCVD and its Phase 1/2 trial of SLN124 in polycythemia vera, as well as expansion of pipeline programs, working capital and general corporate purposes.이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2028 | 15 | -140 | -248 | -185 | 5 |
| 12/31/2027 | 6 | -108 | -199 | -133 | 5 |
| 12/31/2026 | 4 | -67 | -76 | -65 | 6 |
| 3/31/2026 | 1 | -75 | -66 | -66 | N/A |
| 12/31/2025 | 1 | -89 | -62 | -62 | N/A |
| 9/30/2025 | 26 | -65 | -73 | -72 | N/A |
| 6/30/2025 | 27 | -79 | -87 | -87 | N/A |
| 3/31/2025 | 28 | -72 | -71 | -71 | N/A |
| 12/31/2024 | 43 | -45 | -68 | -68 | N/A |
| 9/30/2024 | 18 | -73 | -53 | -53 | N/A |
| 6/30/2024 | 22 | -50 | -36 | -35 | N/A |
| 3/31/2024 | 33 | -44 | -49 | -49 | N/A |
| 12/31/2023 | 32 | -54 | -50 | -49 | N/A |
| 9/30/2023 | 34 | -52 | -50 | -50 | N/A |
| 6/30/2023 | 36 | -53 | -58 | -58 | N/A |
| 3/31/2023 | 29 | -53 | -48 | -48 | N/A |
| 12/31/2022 | 22 | -50 | -58 | -57 | N/A |
| 9/30/2022 | 18 | -40 | -39 | -38 | N/A |
| 6/30/2022 | 19 | -47 | -37 | -36 | N/A |
| 3/31/2022 | 20 | -51 | 4 | 6 | N/A |
| 12/31/2021 | 17 | -53 | 7 | 9 | N/A |
| 9/30/2021 | 15 | -57 | 4 | 5 | N/A |
| 6/30/2021 | 14 | -57 | 2 | 3 | N/A |
| 3/31/2021 | 11 | -49 | -33 | -32 | N/A |
| 12/31/2020 | 7 | -45 | -15 | -15 | N/A |
| 9/30/2020 | 4 | -33 | 0 | 1 | N/A |
| 6/30/2020 | 2 | -28 | 15 | 16 | N/A |
| 3/31/2020 | 1 | -26 | 9 | 9 | N/A |
| 12/31/2019 | 0 | -26 | N/A | 2 | N/A |
| 9/30/2019 | 0 | -23 | N/A | -10 | N/A |
| 6/30/2019 | N/A | -23 | N/A | -23 | N/A |
| 3/31/2019 | N/A | -24 | N/A | -23 | N/A |
| 12/31/2018 | N/A | -23 | N/A | -21 | N/A |
| 9/30/2018 | N/A | -15 | N/A | -20 | N/A |
| 6/30/2018 | N/A | -6 | N/A | -18 | N/A |
| 3/31/2018 | 0 | -4 | N/A | -17 | N/A |
| 12/31/2017 | 0 | -2 | N/A | -13 | N/A |
| 9/30/2017 | 1 | -7 | N/A | -12 | N/A |
| 6/30/2017 | 1 | -12 | N/A | -11 | N/A |
| 3/31/2017 | 1 | -11 | N/A | -12 | N/A |
| 12/31/2016 | 1 | -10 | N/A | -12 | N/A |
| 9/30/2016 | 0 | -10 | N/A | -13 | N/A |
| 6/30/2016 | N/A | -10 | N/A | -12 | N/A |
| 3/31/2016 | N/A | -10 | N/A | -13 | N/A |
| 12/31/2015 | N/A | -10 | N/A | -12 | N/A |
| 9/30/2015 | 0 | -12 | N/A | -13 | N/A |
| 6/30/2015 | 0 | -15 | N/A | -14 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: SLN 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 vs 시장: SLN 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
고성장 수익: SLN 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 대 시장: SLN 의 수익(연간 56.2%)이 US 시장(연간 11.6%)보다 빠르게 성장할 것으로 예상됩니다.
고성장 매출: SLN 의 수익(연간 56.2%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: SLN는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/20 19:49 |
| 종가 | 2026/05/20 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Silence Therapeutics plc는 13명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Howard Miller | Canaccord Genuity |
| Keay Nakae | Chardan Capital Markets, LLC |
| Nathaniel Calloway | Edison Investment Research |